Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis.

Research output: Contribution to journalArticle

Abstract

Experimental studies have suggested that autoimmunity is involved in atherosclerosis and provided evidence that both protective and pro-atherogenic immune responses exist. This concept has received support from small clinical studies implicating autoantibodies directed against apolipoprotein B-100 (apoB-100) in human atherosclerosis. We examined circulating autoantibodies directed against native and malondialdehyde (MDA)-modified epitope p210 of apoB-100 (IgG-p210nat and IgM-p210MDA) in relation to early atherosclerosis in a large, European longitudinal cohort study of healthy high-risk individuals.

Details

Authors
  • Olga McLeod
  • Angela Silveira
  • Gunilla Nordin Fredrikson
  • Karl Gertow
  • Damiano Baldassarre
  • Fabrizio Veglia
  • Bengt Sennblad
  • Rona J Strawbridge
  • Malin Larsson
  • Karin Leander
  • Bruna Gigante
  • Jussi Kauhanen
  • Rainer Rauramaa
  • Andries J Smit
  • Elmo Mannarino
  • Philippe Giral
  • Steve E Humphries
  • Elena Tremoli
  • Ulf de Faire
  • John Ohrvik
  • Anders Hamsten
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cardiac and Cardiovascular Systems
Original languageEnglish
Pages (from-to)242-248
JournalAtherosclerosis
Volume232
Issue number1
Publication statusPublished - 2014
Publication categoryResearch
Peer-reviewedYes